Latest Conference Articles

December 8th 2017, 11:42pm

San Antonio Breast Cancer Symposium

Neoadjuvant treatment with abemaciclib (Verzenio) plus anastrozole induced complete cell cycle arrest as measured by Ki67 for 67.8% of patients with HR-positive/HER2-negative early-stage breast cancer.

December 8th 2017, 11:00pm

San Antonio Breast Cancer Symposium

Older women with HR–positive breast cancer treated with a CDK4/6 inhibitor may derive a progression-free survival benefit similar to that seen in their younger counterparts

December 8th 2017, 7:36pm

San Antonio Breast Cancer Symposium

The PARP inhibitor talazoparib reduced the risk of disease progression or death by 46% versus chemotherapy in patients with BRCA-positive advanced breast cancer.

December 8th 2017, 6:57pm

San Antonio Breast Cancer Symposium

Dawn Hershman, MD, MS, professor of Medicine and Epidemiology, Columbia University Medical Center, discusses the use of acupuncture to treat joint pain caused by aromatase inhibitors in patients with breast cancer.

December 8th 2017, 4:55am

San Antonio Breast Cancer Symposium

Substituting nab-paclitaxel (Abraxane) for solvent-based paclitaxel as neoadjuvant chemotherapy improved disease-free survival in patients with high-risk early breast cancer.

December 8th 2017, 4:23am

San Antonio Breast Cancer Symposium

Susan Domchek, MD, director of the Basser Center for BRCA at Penn Medicine, discusses some questions that remain after the recent phase II MEDIOLA trial.

December 8th 2017, 3:35am

San Antonio Breast Cancer Symposium

Halle Moore, MD, medical oncologist, the Cleveland Clinic, discusses the use of GnRH agonists to preserve ovarian function and fertility in women with breast cancer.

December 8th 2017, 2:12am

San Antonio Breast Cancer Symposium

Treatment with nab-paclitaxel showed promising improvements in overall survival and progression-free survival compared with standard paclitaxel for patients with metastatic triple-negative breast cancer.

December 8th 2017, 1:58am

ASH Annual Meeting and Exposition

Key opinion leaders share their insight on the pivotal and highly anticipated abstracts across hematologic malignancies, including lymphoma, leukemia, and multiple myeloma, ahead of 2017 ASH Annual Meeting and exactly how these findings could be implemented in and affect clinical practice.

December 7th 2017, 11:16pm

San Antonio Breast Cancer Symposium

Investigators with the Austria Breast and Colorectal Cancer Study Group announced today that years can safely be shaved off anastrozole (Arimidex) treatment without affecting disease-free survival postmenopausal HR-positive breast cancer.

December 7th 2017, 11:01pm

San Antonio Breast Cancer Symposium

A mix of traditional and customized acupuncture techniques proved effective in reducing pain and stiffness associated with aromatase inhibitor (AI) therapy in women with early-stage breast cancer.

December 7th 2017, 10:25pm

San Antonio Breast Cancer Symposium

The phase III SOLD trial failed to demonstrate that DFS with 9 weeks of adjuvant trastuzumab was noninferior to the standard 12 months when the 2 regimens were combined with chemotherapy in women with early stage HER2-positive breast cancer.

December 7th 2017, 10:03pm

San Antonio Breast Cancer Symposium

Results from a meta-analysis of data collected from 837 premenopausal women undergoing chemotherapy for early-stage breast cancer suggest that gonadotropin-releasing hormone analog may preserve fertility and have a protective ovarian function.

December 7th 2017, 9:55pm

San Antonio Breast Cancer Symposium

Charles Coombes, MD, professor of medical oncology, Imperial College London, discusses surprising results from a recent study examining celecoxib’s impact on breast cancer progression and relapse.

December 7th 2017, 3:50am

San Antonio Breast Cancer Symposium

Mothaffar F. Rimawi, MD, associate professor and director of clinical research at the Lester and Sue Smith Breast Center at Baylor College of Medicine, discusses the clinical need for immunotherapy regimens for patients with HER2-positive breast cancer.

December 7th 2017, 3:00am

San Antonio Breast Cancer Symposium

Newly released results from the MONALEESA-7 trial showed that adding ribociclib to standard endocrine therapy with temporary ovarian suppression significantly improved progression-free survival as a first-line treatment for pre- and perimenopausal women with advanced HR-positive/HER2-negative breast cancer.

December 7th 2017, 2:03am

San Antonio Breast Cancer Symposium

Julie R. Nangia, MD, assistant professor of medicine, Baylor College of Medicine, discusses some logistical factors that oncologists and health care providers should know regarding implementing a scalp cooling system.

December 7th 2017, 1:07am

San Antonio Breast Cancer Symposium

The combination of pembrolizumab and trastuzumab reached an objective response rate of 15.2% in patients with trastuzumab-resistant, PD-L1–positive, HER2-positive breast cancer.

December 6th 2017, 11:57pm

San Antonio Breast Cancer Symposium

Shortening the intervals between chemotherapy cycles or administering the drugs sequentially reduced early-stage breast cancer recurrence and mortality compared with standard dosing techniques.

December 6th 2017, 11:16pm

San Antonio Breast Cancer Symposium

Treatment with sacituzumab govitecan elicited an objective response rate of 34% in patients with heavily pretreated metastatic triple-negative breast cancer.